Companies: 10,795·Total market cap: $144.5T
Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLANASDAQHealthcare● Active
$105.25
$-3.42(-3.15%)
Market Cap$1.2B
P/E Ratio
52W High$151.18
52W Low$20.2

Palvella Therapeutics, Inc. (PVLA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

pvla · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 11 Wall Street analysts in the past 3 months

SellBuy

Buy

11 analysts

consensus

Rating Breakdown

Strong Buy
1
Buy
10
Hold
0
Sell
0
Strong Sell
0
Total: 11 · Buy rate: 100.0%

12-Month Price Target

High

$255

Consensus

$208

+97.3% upside

Low

$143

Median: $207.5 · Last Close: $105.25

The Palvella Therapeutics, Inc. (PVLA) analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month PVLA price target is $207.67, representing +97.3% upside from the current price of $105.25.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $208 (97.3%)

Consensus Target

$207.67

97.3% upside

High Target

$255

142.3%

Low Target

$143

35.9%

Current Price

$105.25

as of today

Based on analyst price targets, the PVLA stock price prediction for the next 12 months ranges from $143 to $255. The consensus PVLA price forecast of $207.67 implies 97.3% upside from the current price of $105.25.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$102.172.92%

1-day model range: $101.29–$103.06. Peak: $103.06 (-2.92%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$232+120.0%
2028$384+265.2%
2029$524+397.8%
2030$629+497.1%
2031+562.7%
Confidence:MediumCapped at 120% annual limit

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

14%7%79%
2Buy
1Neutral
11Sell
RSI (14)50.2Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · PVLA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$109.77SELL
MA 10$112.96SELL
MA 20$114.55SELL
MA 50$120.79SELL
MA 100$112.81SELL
MA 200$95.44BUY
Current $PVLA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$109.72SELL
EMA 10$111.78SELL
EMA 20$114.53SELL
EMA 50$116.98SELL
EMA 100$111.62SELL
EMA 200$94.67BUY
Current $PVLA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Stephens & Co.2026-05-21
Maintains
OverweightOverweight
Chardan Capital2026-05-21
Maintains
BuyBuy
Chardan Capital2026-03-31
Maintains
BuyBuy
HC Wainwright & Co.2026-03-24
Maintains
BuyBuy
Chardan Capital2026-03-16
Maintains
BuyBuy
Mizuho2026-02-25
Maintains
OutperformOutperform
BTIG2026-02-25
Maintains
BuyBuy
HC Wainwright & Co.2026-02-24
Maintains
BuyBuy
Chardan Capital2026-02-24
Maintains
BuyBuy
BTIG2026-01-29
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Palvella Therapeutics, Inc. (PVLA) stock. Of the recent 42 rating actions, 1 were upgrades and 0 were downgrades. 11 analysts currently cover PVLA.

Analyst Recommendation Trends

Buy ratings927
Hold ratings00
Sell ratings00

PVLA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 9 to 2 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$0M

↓ 100.0% YoY

Revenue Next Year

$31M

↑ 117601.5% YoY

EPS This Year

$-5.56

EPS Next Year

$-6.43

↑ 15.7% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PVLA EPS of $-5.56 for the current fiscal year, based on estimates from 12 analysts. The PVLA revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The PVLA stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PVLA price target is $207.67 (+97.3% upside), with an analyst consensus of Buy.

The PVLA short-term stock prediction for tomorrow is $102.17 (-2.92%). The PVLA stock price prediction for 2027 estimates an average of $232. The PVLA stock prediction for 2030 projects a range of $569–$688.

Palvella Therapeutics, Inc. trades on NASDAQ under the ticker PVLA. The PVLA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

PVLA forecast · 8 questions

According to 11 Wall Street analysts, the average 12-month PVLA price target is $207.67, with a high forecast of $255.00 and a low of $143.00. The median price target is shown in the chart above when available. This implies +97.3% potential upside from the current price of $105.25.

PVLA price targetWhat is PVLA price targetPVLA analyst price targetPVLA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.